SIM-325 by TCR Cure Biopharma Technology for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
SIM-325 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase II drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how SIM-325's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.SIM-325 overviewGene therapy is under development for the treatment of human papillomavirus-associated cancers including head and neck cancer squamous cell carcinoma, nasopharyngeal carcinoma and cervical cancer. The drug candidate is administered through parenteral route. The therapeutic candidate constitutes autologous T cells genetically engineered to express T-cell receptors (TCR) targeting cancer cells expressing an HPV-16 E6 protein.TCR Cure Biopharma Technology overviewTCR Cure Biopharma Technology (Tiankeya), a cutting-edge company in the field of immune cell therapy. The company is headquartered in China. For a complete picture of SIM-325's drug-specific PTSR and LoA scores, buy the report here.
SIM-325 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).
What's Your Reaction?
